918538-04-2

Basic information

• Product Name: PYRROLO[2,1-F][1,2,4]TRIAZINE-2,4-DIONE
• Synonyms: PYRROLO[2,1-F][1,2,4]TRIAZINE-2,4-DIONE;Pyrrolo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione;pyrrolo[1,2-f][1,2,4]triazine-2,4(1H,3H)-dione;Pyrrolo[2,1-f][1,2,4]tria...;Pyrrolo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione (96%);PYRROLO[1,2-D][1,2,4]TRIAZINE-2,4(1H,3H)-DIONE;Pyrrolo[2,1-f][1,2,4]triazine-2,4(1H,3H)
• CAS NO: 918538-04-2
• Molecular Formula: C6H5N3O2
• Molecular Weight: 151.1228
• Mol File: 918538-04-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.74±0.1 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.793
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.92±0.20(Predicted)
• CAS DataBase Reference: PYRROLO[2,1-F][1,2,4]TRIAZINE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: PYRROLO[2,1-F][1,2,4]TRIAZINE-2,4-DIONE(918538-04-2)
• EPA Substance Registry System: PYRROLO[2,1-F][1,2,4]TRIAZINE-2,4-DIONE(918538-04-2)

Safety Data

• Hazardous Substances Data: 918538-04-2(Hazardous Substances Data)

Usage

General Description

PYRROLO[2,1-F][1,2,4]TRIAZINE-2,4-DIONE is a chemical compound with the molecular formula C5H3N5O2. It is a member of the pyrrolo-triazine family and is known for its unique structure and diverse range of applications. The compound exhibits interesting properties that make it useful in various fields such as pharmaceuticals, organic synthesis, and material science. Its structure and reactivity allow for the development of novel drugs, catalysts, and functional materials. Additionally, PYRROLO[2,1-F][1,2,4]TRIAZINE-2,4-DIONE has been studied for its potential biological activities and therapeutic properties, making it an important target for research and development in the scientific community.

InChI:InChI=1/C6H5N3O2/c10-5-4-2-1-3-9(4)8-6(11)7-5/h1-3H,(H2,7,8,10,11)

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 159326-69-9 1-aminopyrrole-2-carboxamide 
• 1003-29-8 2-pyrrole aldehyde 
• 4513-94-4 1H-pyrrole-2-carbonitrile 
• 159326-66-6 N-amino-1H-pyrrole-2-carbonitrile 
• 1379337-32-2 1-(ethoxyformamido)-1H-pyrrole-2-carboxamide 

Downstream Products

• 918538-08-6 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine 
• 1001353-82-7 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde 
• 1001353-78-1 (S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-2-methylpyrrolidine-2-carboxylic acid 

Relevant articles and documents

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted heteroaryl compound and a composition thereof, and applications of the compound and the composition. The compound is a compound as shown in a formula I, or stereoisomer, tautomer, oxynitride, solvate, metabolite, pharmaceutically-acceptable salt or prodrug of the compound as shown in the formula I. The invention also provides a pharmaceutical composition containing the above-mentioned compound; and the above-mentioned compound and the pharmaceutical composition are capable of adjusting the activity of JAK kinases and are applied in prevention, treatment, therapy and alleviation of JAK kinase mediated diseases or disorders.

Heterocyclic amines Hedgehog signal pathway inhibitor

The invention relates to the field of biological medicine, in particular to a heterocyclic amine compound and an application thereof, namely a general formula (I) compound and acceptable salt in the pharmaceutical field. The compound can be used in the Hedgehog signal transduction inhibitor application and various medical applications (please see the formula in the specification). The invention further relates to a preparation method with the general formula (I).

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.